Condition
New Daily Persistent Headache
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
33% success
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Terminated2
Unknown1
Completed1
Recruiting1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05984719Completed
New Daily Persistent Headache Survey
NCT05334927Recruiting
China HeadAche DIsorders RegiStry
NCT05536050Unknown
Study of Low-dose Naltrexone in Chronic Migraine With Fibromyalgia
NCT04260087TerminatedPrimary
New Daily Persistent Headache Biomarkers Study
NCT01920945Phase 2TerminatedPrimary
OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study
Showing all 5 trials